Crinetics Pharmaceuticals, Inc. (CRNX) Institutional Ownership

Ownership Summary

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) showed up in the 13F filings of 232 institutional investors as of December 2025.

• Their combined ownership stood at 112.9% of outstanding shares in December 2025, down from 122.4% in September 2025.
• Their total shares held in CRNX decreased -1.16% quarter over quarter, and separately, investors owning Crinetics Pharmaceuticals decreased 5.31% from a year ago.
• Among the 232 funds, 138 bought more Crinetics Pharmaceuticals shares, 74 sold down, and 20 held their ground.
• Institutional investors collectively held 106.38Mn shares in Crinetics Pharmaceuticals as of December 2025, down by 1.25Mn shares quarter on quarter, and up 5.49Mn shares year over year.
• FMR LLC is the top holder of Crinetics Pharmaceuticals as of December 31, 2025, with 15.76Mn shares representing 16.73% of outstanding stock.
• The most significant purchases of CRNX for the quarter ending December 2025 came from PRICE T ROWE ASSOCIATES INC /MD/ (5.36Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.67Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.64Mn), Janus Henderson Group Plc (4.6Mn), Bellevue Group AG (3.28Mn).
• The biggest sellers of Crinetics Pharmaceuticals for the quarter ending December 2025 included Goldman Sachs Group Inc (506.1K), JENNISON ASSOCIATES LLC (376.93K), UBS Group AG (336.29K), MILLENNIUM MANAGEMENT LLC (237.97K), Neuberger Berman Group LLC (175.15K).
• Business Quant data shows the 10 biggest positions in Crinetics Pharmaceuticals as of December 2025 are held by FMR LLC (15.76Mn), Janus Henderson Group Plc (9.04Mn), BlackRock, Inc. (8.48Mn), FARALLON CAPITAL MANAGEMENT LLC (8.34Mn), WELLINGTON MANAGEMENT GROUP LLP (8.16Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (6.4Mn), PRICE T ROWE ASSOCIATES INC /MD/ (5.36Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.67Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.64Mn), EcoR1 Capital, LLC (4.29Mn).